Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (5477)	10/9/1998 12:10:00 PM
From: Izzy	Read Replies (1) of 6136

I personally don't place much emphasis on the above script numbers, which I presume are US only. How about worldwide sales? How about increased revenues from Viracept sales, US and worldwide? Doctors, in general (not only the HIV specialists), and the patients, are becoming far more knowledgeable about how to appropriately treat HIV patients and it's rather obvious, at least to me, that Viracept is the PI "gold standard" in any efficacious combo treatment regimen, which, I believe, should include at least one PI if our goal is to get AIDS patients into just an HIV+ status (asymptomatic). It's great that the mortality rate has decreased. Now let's decrease the number of AIDS cases and associated diseases, complications.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next